Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br Li N Noticewala SS Williamson CW et

    2019-09-16


    9. Li N, Noticewala SS, Williamson CW, et al: Feasibility of atlas-based active bone marrow sparing intensity modulated Heparin therapy for cervical cancer. Radiother Oncol 123:325-330, 2017
    10. Franco P, Fiandra C, Arcadipane F, et al: Incorporating (18)FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation. BMC Cancer 17:710, 2017
    11. Franco P, Arcadipane F, Ragona R, et al: Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients. Med Oncol 33:72, 2016
    12. Noticewala SS, Li N, Williamson CW, et al: Longitudinal Changes in Active Bone Marrow for Cervical Cancer Patients Treated With Concurrent Chemoradiation Therapy. Int J Radiat Oncol Biol Phys 97:797-805, 2017
    13. Franco P, Arcadipane F, Ragona R, et al: Hematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective. Expert Rev Anticancer Ther 17:335-345, 2017
    14. Myerson Rea: Elective Clinical Target Volumes in Anorectal Cancer: An RTOG Consensus
    Panel
    Contouring Atlas,
    16. Lee AY, Golden DW, Bazan JG, et al: Hematologic Nadirs During Chemoradiation for Anal
    Cancer: Temporal Characterization and Dosimetric Predictors. Int J Radiat Oncol Biol Phys 97:306-312, 2017
    17. Freese C, Sudhoff M, Lewis L, et al: The volume of PET-defined, active bone marrow spared predicts acute hematologic toxicities in anal cancer patients receiving concurrent chemoradiotherapy. Acta Oncol 57:683-686, 2018
    ACCEPTED MANUSCRIPT
    18. Mell LK, Schomas DA, Salama JK, et al: Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 70:1431-7, 2008
    19. Franco P, Ragona R, Arcadipane F, et al: Lumbar-sacral bone marrow dose modeling for acute hematological toxicity in anal cancer patients treated with concurrent chemo-radiation. Med Oncol 33:137, 2016
    20. Franco P, Ragona R, Arcadipane F, et al: Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer. Clin Transl Oncol 19:67-75, 2017
    21. Ben-Josef E, Moughan J, Ajani JA, et al: Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol 28:5061-6, 2010
    22. Fredman ET, Abdel-Wahab M, Kumar AMS: Influence of radiation treatment technique on outcome and toxicity in anal cancer. J Radiat Oncol 6:413-421, 2017
    23. Faivre JC, Peiffert D, Vendrely V, et al: Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03). Radiother Oncol 129:463-470, 2018
    24. Das P, Bhatia S, Eng C, et al: Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 68:794-800, 2007
    25. Crowley C, Winship AZ, Hawkins MA, et al: Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation? Clin Oncol (R Coll Radiol) 21:376-9, 2009
    26. Bartelink H, Roelofsen F, Eschwege F, et al: Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15:2040-9, 1997